Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 13/20 | 0.57 |
| ▸ | CYSLTR2 | Q9NS75 | 12/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.53 |
| ▸ | PPARG | P37231 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4461763 | 0.89 | CYSLTR1 (0.73) | CYSLTR1CYSLTR2EPHX2PPARG | |
| SCHEMBL4461772 | 0.87 | CYSLTR1 (0.61) | CYSLTR1CYSLTR2EPHX2PPARG | |
| SCHEMBL8951214 | 0.87 | CYSLTR2 (0.62) | CYSLTR1CYSLTR2EPHX2 | |
| SCHEMBL9479001 | 0.87 | CYSLTR1 (0.60) | CYSLTR1CYSLTR2EPHX2PPARG | |
| SCHEMBL8951100 | 0.86 | CYSLTR2 (0.53) | CYSLTR1CYSLTR2 | |
| SCHEMBL10367474 | 0.85 | CYSLTR1 (0.63) | CYSLTR1CYSLTR2EPHX2PPARG | |
| SCHEMBL9481066 | 0.84 | CYSLTR1 (0.80) | CYSLTR1CYSLTR2EPHX2PPARG | |
| SCHEMBL10370463 | 0.83 | CYSLTR1 (0.55) | CYSLTR1CYSLTR2EPHX2PPARG | |
| SCHEMBL9478845 | 0.81 | CYSLTR1 (0.54) | CYSLTR1CYSLTR2EPHX2PPARG | |
| SCHEMBL4468802 | 0.80 | CYSLTR1 (0.82) | CYSLTR1CYSLTR2EPHX2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0199543-B1 | HETEROCYCLIC AMIDE DERIVATIVES | ICI AMERICAS INC. (US) | 1991-12-04 | — | — | EP | claimed |
| EP-0199543-A2 | Heterocyclic amide derivatives | ICI AMERICAS INC. (US) | 1986-10-29 | — | — | EP | claimed |
| US-20090317476-A1 | COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A LEUKOTRIENE RECEPTOR ANTAGONIST FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | EPIGENESIS PHARMACEUTICALS, LLC | 2009-12-24 | — | — | US | disclosed |
| EP-1653910-A2 | COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A LEUKOTRIENE RECEPTOR ANTAGONIST FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | Epigenesis Pharmaceuticals LLC (US) | 2006-05-10 | — | — | EP | disclosed |
| US-20050101544-A1 | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease | EPIGENESIS PHARMACEUTICALS, LLC | 2005-05-12 | — | — | US | disclosed |
| WO-2005011595-A2 | COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A LEUKOTRIENE RECEPTOR ANTAGONIST FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | EPIGENESIS PHARMACEUTICALS LLC (US) | 2005-02-10 | — | — | WO | disclosed |
| US-20050026882-A1 | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease | EPIGENESIS PHARMACEUTICALS LLC | 2005-02-03 | — | — | US | disclosed |
| US-5583152-A | Use of N-(4-(5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-ylmethyl)-3 -methoxybenzoyl)-2-methyl-benzenesulphonamide, zafirlukast; allergic asthma, inflammatory diseases, endotoxic conditions or traumatic shock | ZENECA INC. (US) | 1996-12-10 | — | — | US | disclosed |
| US-5440035-A | Leukotriene antagonists; antiallergens, antiinflammatory agents | ZENECA INC. (GB) | 1995-08-08 | — | — | US | disclosed |
| US-5391758-A | Leukotriene antagonists | ZENECA, INC. (US) | 1995-02-21 | — | — | US | disclosed |
| US-5338734-A | Leukotriene antagonist properties; antiinflammatory agents | ZENECA INC. (US) | 1994-08-16 | — | — | US | disclosed |
| US-5179112-A | Leukotriene antagonist as antiallergens and antiinflammatory agents | ICI AMERICAS INC. (US) | 1993-01-12 | — | — | US | disclosed |
| EP-0199543-B1 | HETEROCYCLIC AMIDE DERIVATIVES | ICI AMERICAS INC. (US) | 1991-12-04 | — | — | EP | disclosed |
| US-5030643-A | Antiallergens, antiinflammatory agents | ICI AMERICAS INC. (US) | 1991-07-09 | — | — | US | disclosed |
| US-4859692-A | Heterocyclic amide derivatives and pharmaceutical use | ICI AMERICAS INC. (US) | 1989-08-22 | — | — | US | disclosed |
| EP-0199543-A2 | Heterocyclic amide derivatives | ICI AMERICAS INC. (US) | 1986-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101544-A1 | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease | LTB4R, LTB4R2, CYSLTR1 | CYSLTR1 3/4885CYSLTR2 4/4885EPHX2 296/4885 |
| US-20050026882-A1 | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease | LTB4R2, LTB4R, CYSLTR2 | CYSLTR1 4/4885CYSLTR2 3/4885EPHX2 293/4885 |
| US-20090317476-A1 | COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A LEUKOTRIENE RECEPTOR ANTAGONIST FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | LTB4R, LTB4R2, CYSLTR1 | CYSLTR1 3/4885CYSLTR2 4/4885EPHX2 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.